Key result
Chemotherapy was associated with an increased risk of venous thromboembolism in patients with primary CNS lymphoma, who had an overall 12-month VTE incidence of 13.6%.
Why the study?
Venous thromboembolism and major bleeding in primary central nervous system lymphoma patients were not well described.
What is the incidence and prognostic impact of venous thromboembolism and major bleeding in patients with primary central nervous system lymphoma?
Cohort (n=992)
Yes
What is the incidence and prognostic impact of venous thromboembolism and major bleeding in patients with primary central nervous system lymphoma?
Answers are grounded in this paper and cite their sources.
Patients with primary CNS lymphoma face a high risk of both venous thromboembolism and major bleeding, both of which significantly negatively impact survival.
Venous thromboembolism (VTE) and major bleeding in primary central nervous system lymphoma (PCNSL) patients are not well described. We identified 992 PCNSL patients using the California Cancer Registry (2005–2014). The cumulative incidence of VTE and major bleeding was determined using California hospitalization data. The 12-month cumulative incidence of VTE was 13.6% (95% confidence interval (CI) 11.5–15.8%); chemotherapy and radiation therapy were associated with increased risk of VTE (hazard ratio (HR) 2.41, CI 1.31–4.46 and HR 1.56, CI 1.08–2.25, respectively). The 12-month cumulative incidence of major bleeding was 12.4% (CI 10.1–14.6%). Pulmonary embolism (PE) and proximal deep vein thrombosis were associated with increased risk of major bleeding, likely due to anticoagulation. PE (HR 1.61, CI 1.11–2.33, p=.011) and major bleeding (HR 2.36, CI 1.82–3.06, p<.0001) were associated with increased mortality. This study highlights the high incidence of both VTE and major bleeding and the significant impact on survival for PCNSL patients.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2020) conducted a cohort in Primary central nervous system lymphoma (PCNSL) (n=992). Chemotherapy was evaluated on Venous thromboembolism (VTE) (HR 2.41, 95% CI 1.31-4.46). Chemotherapy was associated with an increased risk of venous thromboembolism in patients with primary CNS lymphoma, who had an overall 12-month VTE incidence of 13.6%.
Synapse has enriched 10 related papers. Consider them for comparative context: